← Back

Anti-TNF vs JAK inhibitors in IBD with PSC

What is the evidence that anti‑TNF agents are more effective than JAK inhibitors in patients with IBD and concomitant PSC

ContestedNot yet clinician-reviewed

What is known

  • The optimal approach for concurrent PSC-IBD is unclear, and no drug to date has effectively reduced PSC-related morbidity or mortality. 1
  • For anti-TNF in PSC, an early randomised controlled trial showed no effect, though retrospective analyses suggest possible benefit. 2
  • JAK inhibitors are described as an emerging/evolving therapy in IBD whose precise role and efficacy, including for liver outcomes, are still being investigated. 1,3

What is unknown / caveats

  • An early RCT of anti-TNF in PSC showed no effect, whereas retrospective analyses suggest possible benefit 2
  • No head-to-head anti-TNF vs JAK-inhibitor trial in PSC-IBD in the retrieved evidence
  • PSC-specific anti-TNF data are largely retrospective and conflicting
  • Whether any IBD therapy class improves liver-related outcomes in PSC-IBD remains unestablished.

References

  1. Pinnuck B, Lynch KD. Navigating the pharmacotherapeutic management of comorbid inflammatory bowel disease and primary sclerosing cholangitis. Expert Opin Pharmacother. 2024. PMID: 39316754.
  1. Lynch KD, Keshav S, Chapman RW. The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Curr Hepatol Rep. 2019. PMID: 31008013.
  1. Parra-Izquierdo V, Ardila O, Márquez JR, Riveros J, Gómez-Venegas ÁA, Medrano-Almanza CA, Ballesteros M, Barreto-Pérez J, Frias-Ordoñez JS. REAL-WORLD EXPERIENCE WITH JANUS KINASE INHIBITORS IN EXTRAINTESTINAL MANIFESTATIONS AND INFLAMMATORY BOWEL DISEASE IN COLOMBIA: A COMPARATIVE STUDY (JAKEIM-IBD STUDY). Arq Gastroenterol. 2026. PMID: 41538670.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.


Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.

Reviewer notes

answered 2026-08-04 · corpus build d04e93d4 · faithfulness 0.8421052631578947